Cancer Treatment with Actinomycin-D and Vincristine

A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer

Protocol Description

The purpose of this Children's Oncology Group study is to gain a better understanding of what happens to the drugs Actinomycin-D (dactinomycin) and/or vincristine after they are administered to children for treatment of cancer. Both drugs have been used for more than 40 years, but doctors still don’t know why some children develop serious side effects, while others do not. Through blood and urine sampling, researchers will study how these drugs react and are processed by the body.

Eligibility Criteria

Boys and girls up to age 17 who are diagnosed with cancer and being treated with dactinomycin and/or vincristine will be eligible for consideration in the study.
Boys: Up to age 17
Girls: Up to age 17

Urine and blood samples will be taken in conjunction with the child’s chemotherapy with dactinomycin and vincristine. Blood samples will be taken on the day of chemotherapy, once the next day and once 2 to 4 days later.
Frequency of visits: 4 consecutive days
Duration: 6 months of follow-up

Status: Open For Enrollment

Sources of Support
Children’s Oncology Group
National Cancer Institute

Additional Resources
Study Description at National Institutes of Health

Contact Information

To get started, please contact:
Sharon DiBridge, CRA

Angela Connelly, Research RN, BSN

Last Update
January 7, 2015
  • Increase/Decrease Text Size
  • Print This Page
Last Update
January 7, 2015